Division of Urology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA.
Oncology (Williston Park). 2010 Dec;24(14):1308-13, 1318.
Prostate cancer will be diagnosed in one of six men during their lifetimes, and a small portion of these will progress after primary and salvage therapies. For many years, there were few treatment options for these patients after routine hormonal maneuvers, and standard of care since the early 2000s has consisted primarily of docetaxel, which improved survival over the previous first-line therapy mitoxantrone. In recent years, however, new therapies have begun to emerge to treat this devastating form of prostate cancer. This review examines the mechanisms behind these therapeutics and the key trials seeking to validate their clinical use.
前列腺癌将在 6 名男性中的 1 名一生中被诊断出来，其中一小部分患者在原发性和挽救性治疗后会进展。多年来，在常规激素治疗后，这些患者的治疗选择很少，自 21 世纪初以来，标准治疗主要是多西他赛，其改善了生存情况优于之前的一线治疗米托蒽醌。然而，近年来，新的治疗方法开始出现，以治疗这种毁灭性的前列腺癌。本综述探讨了这些治疗方法背后的机制以及寻求验证其临床应用的关键试验。
